• Advancing gastrointestinal health naturally

    Our Gastrointestinal ReProgramming (GaRP) product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with gastrointestinal disorders. More >>

  • Unite for World IBD Day

    This Sunday, 19th May 2019, Anatara Lifesciences will support the global campaign aimed at raising IBD awareness. More than 10 million people worldwide live with Crohn’s disease or Ulcerative colitis. On World IBD Day, we’re asking YOU to join with us to build awareness of these debilitating digestive diseases. More >>


    Anatara Lifesciences CEO Steve Lydeamore sat down with Ky Chow at Proactive Investors last month to talk about the healthcare company’s renewed focus on human health, targeting the 11% of Australians affected by irritable bowel syndrome (IBS). Please click here to watch the interview. More >>

  • Successful Dietary Supplement Proof of Concept Studies

    Anatara’s unique Gastrointestinal ReProgramming (GaRP) dietary supplement has been shown to significantly reduce inflammation and protect and maintain gut integrity in recent in vitro studies. More >>

  • Anatara Lifesciences brings new hope for sufferers of IBS

    Anatara has welcomed IBS Awareness Month this April with news that it is developing a new dietary supplement for sufferers of Irritable Bowel Syndrome (IBS) that will help manage the condition and its associated symptoms. More >>

Company description

Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. The Company is focused on building a pipeline of human gastrointestinal health products.

Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Recent coverage



More Events


Investors Home